Last 0.38 GBp
Change Today 0.00 / 0.00%
Volume 1.8M
VAL On Other Exchanges
Symbol
Exchange
London
As of 5:35 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

valirx plc (VAL) Snapshot

Open
0.38 GBp
Previous Close
0.38 GBp
Day High
0.38 GBp
Day Low
0.38 GBp
52 Week High
10/25/13 - 0.71 GBp
52 Week Low
04/28/14 - 0.26 GBp
Market Cap
11.1M
Average Volume 10 Days
30.2M
EPS TTM
-0.0019 GBp
Shares Outstanding
2.9B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALIRX PLC (VAL)

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx Plc, an investment holding company, is engaged in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of rebellious genes, which cause cancers, inflammatory conditions, and Alzheimer’s and autoimmune diseases. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a novel peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It is also developing ValiFinn BioMarkers that are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer; and predictive markers of disease progression, as well as VAL401, a clinical drug to treat patients with lung cancer. The company is based in London, the United Kingdom.

9 Employees
Last Reported Date: 03/28/14

valirx plc (VAL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 182.5K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 74.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 118.0K GBP
Compensation as of Fiscal Year 2013.

valirx plc (VAL) Key Developments

ValiRx plc Announces Joint Venture with Tangent Reprofiling Ltd

ValiRx Plc announced that it had set up a majority-owned joint venture with Tangent Reprofiling Ltd. to advance the development of a lung cancer drug.

ValiRx plc Announces New Office Address

ValiRx Plc announced that it has moved offices to better accommodate its growing team. The company's new office address is: 3rd Floor, 16 Upper Woburn Place, London, WC1H 0BS.

ValiRx plc Provides Development Update

ValiRx Plc provided a positive development and scientific update on the first month's progress at ValiSeek Limited, ValiRx's joint venture company with Tangent Reprofiling Limited. ValiSeek was formed to progress the novel cancer treatment VAL401 through its remaining preclinical development and towards clinical Phase II trials for the treatment of lung cancer and other oncology indications. The company reported that key results from non-regulatory toxicology studies confirmed that the VAL401 formulation is well tolerated in dosing schedule. These results therefore allow ValiSeek to plan future detailed regulatory toxicology and pharmacokinetic studies with greater confidence in securing a positive outcome for clinical studies. Furthermore, the combination of components in the reformulation showed comparable results to prior data from the previous clinical usage of the drug permitting ValiSeek to better understand the regulatory route through to the clinic. Further in vitro results have encouraged ValiSeek to investigate the precise subsets of patients suitable for clinical treatment with VAL401. Specifically, non-small cell lung cancer (adenocarcinoma, non-squamous) and small cell lung adenocarcinoma cell lines responded well to VAL401 treatment in vitro, expanding previous results. ValiSeek is now able to identify which cell lines to take forward into the next stage of studies and to make better informed clinical decisions on the selection of trial patients. Further to the lung cancer indication, new results have indicated potential utility in pancreatic cancer, with the cellular in vitro assay with pancreatic cancer cells responding in a comparable degree to the lung cancer cells. This complements earlier studies by Tangent, which also suggest utility in both prostate cancer and breast cancer, demonstrating the potential for broad spectrum use of VAL401 against solid adenocarcinoma tumours or cancers of hormone responsive glandular origin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 0.38 GBp 0.00

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.9x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.